- Product Listings
- Compare Products
- Calculators
- Product Tours
- Expert Reviews
- Our Experts
- Company Directory
- About Beye
- Contact Us
Ⓒ 2024 Beye.com. All rights reserved.
This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.
Moxeza
Alcon, a Novartis DivisionMoxeza (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerococcus viridans*, Corynebacterium macginleyi*, Enterococcus faecalis*, Micrococcus luteus*, Staphylococcus arlettae*, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus*, Staphylococcus warneri*, Streptococcus mitis*, Streptococcus pneumoniae, Streptococcus parasanguinis*, Escherichia coli*, Haemophilus influenzae, Klebsiella pneumoniae*, Propionibacterium acnes, Chlamydia trachomatis* *Efficacy for this organism was studied in fewer than 10 infections.
At-a-Glance
- Mechanism of Action: The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.
- Dosage: Instill 1 drop in the affected eye(s) 2 times daily for 7 days.
Details
FDA
Yes
CE Mark
Not specified
Active Ingredients
Moxifloxacin hydrochloride
Application
Topical
Status
Prescription
Strength
0.5%
Company Information
Contact the company for additional information, availability, or pricing:
Alcon, a Novartis Division
alcon.com6201 South Freeway
Fort Worth, TX 76134
Trending in Ophthalmic Drugs
Powered by:
Glaucoma Research Highlights
MillennialEye, May/June '18
Intracameral Endophthalmitis Prophylaxis: Where We Stand
MillennialEye, May/June '18
Pseudophakic Bullous Keratopathy
CRSToday, April 2018
Troubleshooting Nonwetting Scleral Lenses
CollaborativeEye, Mar/Apr '18
Innovations in Diabetic Eye Disease
CollaborativeEye, Mar/Apr '18
Options Expanding for IOP Lowering
CollaborativeEye, Mar/Apr '18
Newly Approved Glaucoma Therapy Increases Options for Patients and Providers
CRSToday, March 2018
Cataract Surgery After LASIK Corneal Flap Removal
Karl G. Stonecipher, MD
CRSToday, March 2018
Small Bottles…Big Issues
Robert J. Weinstock, MD
CRSToday, March 2018
Lessons from the PHACO Study
Eric D. Donnenfeld, MD
CollaborativeEye, Debut Issue
Mentors Pave the Way
CRSToday, January 2018
Bye Bye, Dry Eye
Gregg J. Berdy, MD, FACS
CRSToday, January 2018
Post-Traumatic Iris Cyst Requiring Ethanol Irrigation
MillennialEye, May/June '17
Don’t Miss EBMD
CRSToday, Jan 2016
My Algorithm for DED
CRSToday, Jan 2016
Show More
